Future of Bispecifics and CAR T in R/R MM

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

EP: 5.Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

Now Viewing

EP: 6.Future of Bispecifics and CAR T in R/R MM

EP: 7.Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

EP: 8.Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

EP: 9.Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

EP: 10.Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

EP: 11.Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL

EP: 12.Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

Video content above is prompted by the following:

Future of Bispecifics and CAR T in R/R MM:

The treatment landscape for R/R MM is evolving, with CAR T therapies and bispecific antibodies emerging as key modalities:

• CAR T Therapy: Anitocabtagene autoleucel adds to the growing body of evidence supporting personalized, deep, and durable responses in R/R MM, although accessibility and manufacturing time remain challenges.
• Bispecific Antibodies: Off-the-shelf alternatives offer flexibility and repeated dosing advantages, with ongoing trials optimizing sequencing and combination strategies.

Future research will focus on sequencing, combination approaches, and bridging strategies to enhance outcomes and accessibility in R/R MM treatment.